Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
RAPT Therapeutics, Inc. - Common Stock
(NQ:
RAPT
)
57.68
+0.05 (+0.09%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about RAPT Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
November 11, 2024
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
November 06, 2024
Via
Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 04, 2024
Via
Benzinga
RAPT Therapeutics: Q4 Earnings Insights
↗
March 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
October 02, 2024
Via
Benzinga
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024
↗
August 08, 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
August 08, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
June 03, 2024
Via
Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
↗
May 21, 2024
Via
Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm
May 09, 2024
From
Schall Law
Via
GlobeNewswire
What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
↗
May 09, 2024
RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure.
Via
Benzinga
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024
↗
May 09, 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
May 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
May 09, 2024
Via
Benzinga
RAPT Therapeutics Reports First Quarter 2024 Financial Results
May 09, 2024
Company maintains solid cash position of $141.6 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
April 09, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
3 Biotech Stocks to Dump Before They Go to Zero
↗
April 09, 2024
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling.
Via
InvestorPlace
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
March 11, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023
↗
March 07, 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 07, 2024
Company maintains solid cash position of $158.9 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
February 26, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Rivian Automotive Reports Q4 Loss, Joins Etsy, Lucid Group And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
February 22, 2024
U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 2% on Thursday.
Via
Benzinga
What's Going On With RAPT Therapeutics Stock On Wednesday?
↗
February 21, 2024
Latest developments in RAPT Therapeutics as FDA places clinical hold on Phase 2b trial for zelnecirnon in dermatitis and asthma. Stock rebounds and analyst downgrades.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
February 21, 2024
Via
Benzinga
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
February 21, 2024
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly...
Via
Benzinga
Stocks Slip Ahead Of Fed Minutes, Nvidia Earnings
↗
February 21, 2024
Stocks are lower today, with the Nasdaq Composite Index (IXIC) leading the losses as investors reassess a potentially overvalued tech sector.
Via
Talk Markets
Topics
Economy
Stocks
Crude Oil Moves Lower; Summit Therapeutics Shares Plummet
↗
February 20, 2024
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 200 points on Tuesday. The Dow traded down 0.18% to 38,557.86 while the NASDAQ fell 1.30% to 15,570.84. The...
Via
Benzinga
Topics
Stocks
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
February 20, 2024
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
February 20, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
